Naglazyme Articles
BioMarin to acquire LEAD Therapeutics for $18 million plus $68 million more on milestone
5 February 2010
BioMarin's 1st-qtr beats analyst expectations
12 May 2008
AnGes launches BioMarin's Naglazyme in Japan
21 April 2008
BioMarin/AnGes' Naglazyme approved in Japan
7 April 2008
Humira and Naglazyme recommended for approval in Japan
10 March 2008
BioMarin partner submits Naglazyme BLA in Japan
20 August 2007
BioMarin's 2nd-qtr 2007 loss widens to $3.9M
20 August 2007
BioMarin's Naglazyme approved in Europe
6 February 2006
BioMarin's Naglazyme debuts in the USA
27 June 2005
BioMarin's Naglazyme gets FDA clearance
13 June 2005
BioMarin's rhASB gets FDA priority review
7 February 2005
BioMarin submits EU file on Aryplase for MPS VI
13 December 2004
Showing 1-13 of 13 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
